4883 Share Price Performance
JP¥0
-79.00 (-100.00%)
Price JP¥0
Share Pricen/a
Is Modalis Therapeutics (TSE:4883) Using Too Much Debt?
Dec 19
Modalis Therapeutics Corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
4883 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Modalis Therapeutics Corporation Key Details
About 4883
- Founded
- 2016
- Employees
- 17
- CEO
- WebsiteView website
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology developed by Modalis that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
